Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mexiletine PR vs IR in Non-Dystrophic Myotonias
NCT07097701Phase 3Recruiting
- Sponsor
- Lupin Limited
- Start
- Sep 2025
- Primary completion
- Jan 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of mexiletine in myotonia congenita (MC), paramyotonia congenita (PMC), sodium channel myotonia (SCM), sponsored by Lupin Limited. Started Sep 2025; status: recruiting.
02
Drugs
mexiletine
03
Conditions
myotonia congenita (MC)paramyotonia congenita (PMC)sodium channel myotonia (SCM)
Beyond the preview
Go deeper on NCT07097701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07097701.